Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
Total Valuation
Dianthus Therapeutics has a market cap or net worth of $4.21B. The enterprise value is $3.00B.
Market Cap$4.21B
Enterprise Value$3.00B
Share Statistics
Dianthus Therapeutics has 52,942,080 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding52,942,080
Owned by Insiders0.15%
Owned by Institutions50.16%
Financial Efficiency
Dianthus Therapeutics’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -35.55%.
Return on Equity (ROE)-0.33
Return on Assets (ROA)-0.31
Return on Invested Capital (ROIC)-35.55%
Return on Capital Employed (ROCE)-0.36
Revenue Per Employee26.10K
Profits Per Employee-2.08M
Employee Count78
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Dianthus Therapeutics is ―. Dianthus Therapeutics’s PEG ratio is -0.15.
PE Ratio―
PS Ratio764.98
PB Ratio3.16
Price to Fair Value3.16
Price to FCF-12.05
Price to Operating Cash Flow-23.27
PEG Ratio-0.15
Income Statement
In the last 12 months, Dianthus Therapeutics had revenue of 2.04M and earned -162.34M in profits. Earnings per share was -4.20.
Revenue2.04M
Gross Profit2.04M
Operating Income-177.93M
Pretax Income-162.34M
Net Income-162.34M
EBITDA-177.93M
Earnings Per Share (EPS)-4.20
Cash Flow
In the last 12 months, operating cash flow was -129.06M and capital expenditures -213.00K, giving a free cash flow of -129.27M billion.
Operating Cash Flow-129.06M
Free Cash Flow-129.27M
Free Cash Flow per Share-2.44
Dividends & Yields
Dianthus Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.09
52-Week Price Change372.07%
50-Day Moving Average60.23
200-Day Moving Average38.60
Relative Strength Index (RSI)67.94
Average Volume (3m)1.00M
Important Dates
Dianthus Therapeutics upcoming earnings date is May 7, 2026, TBA (Confirmed).
Last Earnings DateMar 9, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Dianthus Therapeutics as a current ratio of 13.32, with Debt / Equity ratio of 0.28%
Current Ratio13.32
Quick Ratio13.32
Debt to Market Cap<0.01
Net Debt to EBITDA0.28
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Dianthus Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Dianthus Therapeutics EV to EBITDA ratio is -8.47, with an EV/FCF ratio of -11.66.
EV to Sales740.57
EV to EBITDA-8.47
EV to Free Cash Flow-11.66
EV to Operating Cash Flow-11.68
Balance Sheet
Dianthus Therapeutics has $404.30M in cash and marketable securities with $1.39M in debt, giving a net cash position of $402.91M billion.
Cash & Marketable Securities$404.30M
Total Debt$1.39M
Net Cash$402.91M
Net Cash Per Share$7.61
Tangible Book Value Per Share$13.05
Margins
Gross margin is 100.00%, with operating margin of -8739.34%, and net profit margin of -7973.33%.
Gross Margin100.00%
Operating Margin-8739.34%
Pretax Margin-7973.33%
Net Profit Margin-7973.33%
EBITDA Margin-8739.34%
EBIT Margin-8739.34%
Analyst Forecast
The average price target for Dianthus Therapeutics is $127.42, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$127.42
Price Target Upside60.38% Upside
Analyst ConsensusStrong Buy
Analyst Count15
Revenue Growth Forecast-42.64%
EPS Growth Forecast-39.78%